Encorafenib: risk of tumour lysis syndrome | springermedicine.com

Springer Medicine

Top

Reactions Weekly

Published in:

01-12-2023 | Media release

Encorafenib: risk of tumour lysis syndrome

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

A safety signal of encorafenib and the risk of tumour lysis syndrome has been detected following a review by the Saudi Food and Drug Authority (SFDA). …

Saudi Food and Drug Authority (SFDA). Safety signal of encorafenib and the risk of tumour lysis syndrome. Internet Document : 21 Nov 2023. Available from: URL: https://www.sfda.gov.sa/sites/default/files/2023-11/Encorafenib%20and%20Risk%20of%20Tumour%20lysis%20syndrome%20-%20Signal%20communication.pdf

Title: Encorafenib: risk of tumour lysis syndrome
Publication date: 01-12-2023
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-51306-9

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties